Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $51.51 which represents a slight increase of $2.40 or 4.89% from the prior close of $49.11. The stock opened at ...

A phase 2b trial of Viking Therapeutics' (NASDAQ:VKTX) VK2809 found that those on the medicine saw statistically significant ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The ...

Viking Therapeutics' shares have soared 200% since January. Its leading candidate for treating obesity helps justify its valuation. The company also has several other medicines in the pipeline.

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech that rose in prominence this year. The drugmaker's shares ...